Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE).
The present study investigated the rate of catabolism of CR1 (the C3b receptor, CD35) on erythrocytes (E) in vivo, in relationship with the expressed number of CR1/E, the CR1.1 HindIII quantitative CR1 polymorphism, and cell age. The relationship between the number of CR1/E and cell age was analysed by measuring G6PDH activity in E that had been sorted according to high or low expression of CR1 (CD35), by assessing the expression of CR1 (CD35) on E separated according to cell density, and by comparing the number of CR1 (CD35) antigenic sites on reticulocytes and on E. A physiological catabolism of CR1 (CD35) manifested by a reduction in the number of CR1 (CD35) antigenic sites/E with cell ageing was consistently observed in healthy individuals. The number of CR1/E decreased with ageing of E according to a complex pattern that associated an exponential decay and an offset. Calculated half-lives of CR1 (CD35) ranged between 11 and 32 days in healthy individuals. A more rapid loss of CR1 (CD35) with cell ageing occurred on cells from individuals expressing high numbers of CR1/E. In patients with systemic lupus erythematosus (SLE), half-lives of CR1 (CD35) on E were in the same range as those of healthy individuals with a similar quantitative CR1 genotype; the number of CR1 (CD35) on reticulocytes was reduced and linearly related to the number of CR1/E, independently of the patients' quantitative CR1 genotype. Transfusion experiments with E bearing high or low amounts of CR1/E indicated the lack of preferential removal of E bearing high numbers of CR1 (CD35) in patients with SLE. These results indicate that the rate of loss of CR1 (CD35) from E with cell ageing is directly related to the quantitative CR1 phenotype and suggest that enhanced peripheral catabolism is not the sole mechanism of the acquired loss of CR1 (CD35) on E in patients with SLE.
Cohen
J H
JH
Laboratoire d'Immunologie, CHU Robert Debré, Reims, France.
Lutz
H U
HU
Pennaforte
J L
JL
Bouchard
A
A
Kazatchkine
M D
MD
D015703:Antigens, CD / Q000378:metabolism; D002452:Cell Count; D002469:Cell Separation; D003179:Complement C3b / Q000378:metabolism*; D004912:Erythrocytes / Q000378:metabolism*; D005434:Flow Cytometry; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism*; D011951:Receptors, Complement / Q000378:metabolism*; D017463:Receptors, Complement 3b
D015703:Antigens, CD; D011951:Receptors, Complement; D017463:Receptors, Complement 3b; D003179:Complement C3b; D005954:Glucosephosphate Dehydrogenase